<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: risks could materially", fill: "#5b92e5"},
{source: "2: risks could materially", target: "2: adversely affect", fill: "#5b92e5"},
{source: "2: adversely affect", target: "2: financial condition", fill: "#5b92e5"},
{source: "2: risks could materially", target: "4: Additional ", fill: "#7cfc00"},
{source: "4: Additional ", target: "4: present significant risks", fill: "#7cfc00"},
{source: "4: present significant risks", target: "4: also impair", fill: "#7cfc00"},
{source: "4: also impair", target: "4: operations", fill: "#7cfc00"},
{source: "4: Additional ", target: "5: should also refer", fill: "#4b5320"},
{source: "5: should also refer", target: "5: incorporated by reference", fill: "#4b5320"},
{source: "5: incorporated by reference", target: "5: Annual Report ", fill: "#4b5320"},
{source: "5: Annual Report ", target: "5: future success", fill: "#4b5320"},
{source: "5: future success", target: "5: depends on", fill: "#4b5320"},
{source: "5: depends on", target: "5: development manufacture", fill: "#4b5320"},
{source: "5: development manufacture", target: "5: new products", fill: "#4b5320"},
{source: "5: should also refer", target: "6: largely dependent upon", fill: "#21abcd"},
{source: "6: largely dependent upon", target: "6: manufacture", fill: "#21abcd"},
{source: "6: largely dependent upon", target: "15: deliveries", fill: "#1c352d"},
{source: "15: deliveries", target: "15: PARSEC System ", fill: "#1c352d"},
{source: "15: PARSEC System ", target: "15: laboratories", fill: "#1c352d"},
{source: "15: laboratories", target: "15: the FDA for the PARSEC System in the United States", fill: "#1c352d"},
{source: "15: deliveries", target: "184: assumptions", fill: "#ffa500"},
{source: "184: assumptions", target: "184: preparation", fill: "#ffa500"},
{source: "184: preparation", target: "184: accordance", fill: "#ffa500"},
{source: "184: accordance", target: "184: United States GAAP Any ", fill: "#ffa500"},
{source: "184: assumptions", target: "START_HERE", fill: "#ffa500"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_royale">Manufacture royale</a></td>
      <td>Manufacture Royale is a Swiss luxury watch brand. Founded in the eighteenth century, the brand was revived in 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Parsec">Parsec</a></td>
      <td>The parsec (symbol: pc) is a unit of length used to measure the large distances to astronomical objects outside the Solar System, approximately equal to 3.26 light-years or 206,000 astronomical units (au), i.e. 30.9 trillion kilometres (19.2 trillion miles).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Parsec_(software)">Parsec (software)</a></td>
      <td>Parsec is a proprietary desktop capturing application primarily used for playing games through video streaming. Using Parsec, a user can stream video game footage through an Internet connection, allowing one to run a game on one computer but play it remotely through another device.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Parsec_(parser)">Parsec (parser)</a></td>
      <td>Parsec is a library for writing parsers in Haskell. It is based on higher-order parser combinators, so a complicated parser can be made out of many smaller ones.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Binary_black_hole">Binary black hole</a></td>
      <td>A binary black hole (BBH) is a system consisting of two black holes in close orbit around each other. Like black holes themselves, binary black holes are often divided into stellar binary black holes, formed either as remnants of high-mass binary star systems or by dynamic processes and mutual capture; and binary supermassive black holes, believed to be a result of galactic mergers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Exoplanet">Exoplanet</a></td>
      <td>An exoplanet or extrasolar planet is a planet outside the Solar System. The first possible evidence of an exoplanet was noted in 1917 but was not recognized as such.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Astronomical_unit">Astronomical unit</a></td>
      <td>The astronomical unit (symbol: au, or AU or AU) is a unit of length, roughly the distance from Earth to the Sun and equal to 150 million kilometres (93 million miles) or 8.3 light minutes. The actual distance from Earth to the Sun varies by about 3% as Earth orbits the Sun, from a maximum (aphelion) to a minimum (perihelion) and back again once each year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assumption_of_Mary">Assumption of Mary</a></td>
      <td>The Assumption of Mary is one of the four Marian dogmas of the Catholic Church. (The word 'assumption' derives from the Latin word assūmptiō meaning "taking up").</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strategic_assumptions">Strategic assumptions</a></td>
      <td>Strategic assumptions are the assumptions that are held by decision-makers when building a strategic plan. All strategic plans should be built upon a grounded, validated and accepted set of strategic assumptions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shattered_assumptions_theory">Shattered assumptions theory</a></td>
      <td>In social psychology, shattered assumptions theory proposes that experiencing traumatic events can change how victims and survivors view themselves and the world. Specifically, the theory – developed by Ronnie Janoff-Bulman in 1992 – concerns the effect that negative events have on three inherent assumptions: overall benevolence of the world, meaningfulness of the world, and self worth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assumption-based_planning">Assumption-based planning</a></td>
      <td>Assumption-based planning in project management is a post-planning method that helps companies to deal with uncertainty. It is used to identify the most important assumptions in a company's business plans, to test these assumptions, and to accommodate unexpected outcomes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Economic_entity">Economic entity</a></td>
      <td>In accounting, an economic entity is one of the assumptions made in generally accepted accounting principles. Almost any type of organization or unit in society can be an economic entity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assumption_Island">Assumption Island</a></td>
      <td>Assumption Island is a small island in the Outer Islands of Seychelles north of Madagascar, 1,135 km (705 mi) south-west of the capital, Victoria, on Mahé Island.\nIn 2018, Seychelles and India signed an agreement to build and operate a joint military facility on a portion of the island, which the National Assembly of Seychelles refuted the agreement and deemed after protestation by the citizens of Seychelles.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IVAX DIAGNOSTICS INC      ITEM 1A RISK FACTORS          You <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below</td>
    </tr>
    <tr>
      <td>These and other     <font color="blue">risks could <font color="blue">materially</font></font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business, operating results     or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are not the only risks we     face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not presently known to us or other factors that we do     not presently perceive to <font color="blue">present <font color="blue">significant</font> risks</font> to us at this time may     <font color="blue">also impair</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should also refer</font> to the other information     contained or <font color="blue">incorporated by reference</font> in this <font color="blue">Annual Report </font>on Form 10-K         The <font color="blue">future success</font> of our business <font color="blue">depends on</font> our <font color="blue">development</font>, <font color="blue">manufacture</font>     and marketing of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Our  future  success is <font color="blue">largely dependent upon</font> our ability to develop,     <font color="blue">manufacture</font> and market <font color="blue">commercially</font> successful new scientific <font color="blue">instruments</font>     and assays</td>
    </tr>
    <tr>
      <td>Delays in the <font color="blue">development</font>, <font color="blue">manufacture</font> or marketing of new     <font color="blue">products will impact</font> our operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Each of     the steps in the <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing of our products, as     well as the <font color="blue">process taken as</font> a whole, involves <font color="blue">significant</font> periods of time     and expense</td>
    </tr>
    <tr>
      <td>There can be no assurance that:           •   any of our products presently under <font color="blue">development</font>, if and when fully     developed and tested, will perform as expected,           •   we will obtain <font color="blue">necessary <font color="blue"><font color="blue">regulatory</font> approval</font>s</font> in a <font color="blue">timely manner</font>, if     at all, or           •   we can <font color="blue">successfully</font> and profitably produce and market any of our     products</td>
    </tr>
    <tr>
      <td>6     ______________________________________________________________________       Any of the above <font color="blue">factors may <font color="blue">materially</font></font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business,     prospects, operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our  strategic  <font color="blue">initiatives</font>,  including  our  <font color="blue">automation strategy</font>, our     <font color="blue">development</font> and <font color="blue">commercial release</font> of our <font color="blue">new <font color="blue">proprietary</font></font> instrument system     and the expansion of our test kit menu, may not be successful</td>
    </tr>
    <tr>
      <td>Our  test  kits  are designed to be performed <font color="blue">either manually</font> or in an     <font color="blue">automated format</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also design</font> and <font color="blue">manufacture</font> our <font color="blue">laboratory <font color="blue">instruments</font></font>     to perform tests in a fully-automated mode</td>
    </tr>
    <tr>
      <td>In furtherance of our automation     strategy, we have developed a <font color="blue">new <font color="blue">proprietary</font></font> instrument system, named the     PARSEC^™  System</td>
    </tr>
    <tr>
      <td>While <font color="blue">deliveries</font> of the PARSEC^™ System to customer     <font color="blue">laboratories</font> abroad have already begun, we intend to seek 510(k) clearance     from the FDA for the PARSEC^™ System in the United States</td>
    </tr>
    <tr>
      <td>Accordingly,     commercial <font color="blue">deliveries</font> of the PARSEC^™ System in the <font color="blue">United States </font>will await     <font color="blue"><font color="blue">regulatory</font> clearance</font> of the 510(k)</td>
    </tr>
    <tr>
      <td>Furthermore, there can be no assurance that our     <font color="blue">international</font> <font color="blue">activities</font> <font color="blue">associated with</font> the PARSEC^™ System will not be     <font color="blue">impacted by</font> the delay in the full <font color="blue">commercial launch</font> of the PARSEC^™ System     in the United States</td>
    </tr>
    <tr>
      <td>We expect that the PARSEC™ System will become our <font color="blue">primary product</font> and will     <font color="blue">position us</font> to <font color="blue">target new product markets</font> for <font color="blue">growth beyond</font> the <font color="blue">niche market</font>     for autoimmune and <font color="blue"><font color="blue">infectious disease</font> immunoassay products</font> in which we     <font color="blue">currently compete</font></td>
    </tr>
    <tr>
      <td>However, the <font color="blue">development</font> and marketing of new or enhanced     products is a complex and uncertain process</td>
    </tr>
    <tr>
      <td>Accordingly, we cannot be     certain that:           •   the PARSEC^™ System will be available when or perform as expected,           •   the PARSEC^™ System will become our <font color="blue">primary product</font>,           •   the PARSEC^™ System <font color="blue">will enable us</font> to expand the menu of test kits we     offer,           •   we will be successful in the marketing of the PARSEC^™ System, or           •   customers will integrate the PARSEC^™ System into their <font color="blue">operations</font> as     <font color="blue">readily as</font> expected</td>
    </tr>
    <tr>
      <td>Additionally,  in  an  effort to expand the test kit menu we offer, in     <font color="blue">September  </font>2004,  we  <font color="blue">entered into</font> a <font color="blue">license <font color="blue">agreement</font> with</font> an <font color="blue">Italian     </font><font color="blue"><font color="blue">diagnostic</font>s</font>  company  that  allows  us  access  to  its <font color="blue">technology</font> for     <font color="blue">manufacturing certain <font color="blue">hepatitis</font> products</font></td>
    </tr>
    <tr>
      <td>We expect this <font color="blue">agreement</font> to enable     us  to  become  <font color="blue">competitive</font> in <font color="blue">markets outside</font> of the <font color="blue">United States </font>by     providing us with <font color="blue">technology</font> that, over time, <font color="blue">would allow us</font> to <font color="blue">internally</font>     <font color="blue">manufacture</font> many of our own <font color="blue">hepatitis</font> products with the “CE Marking,” as     well as <font color="blue">internally</font> <font color="blue">manufacture</font> our own <font color="blue">raw materials</font> for those <font color="blue">hepatitis</font>     products</td>
    </tr>
    <tr>
      <td>However, <font color="blue">there remains</font> a risk that we will not be able to obtain     product <font color="blue">technology</font> that <font color="blue">would enable us</font> to <font color="blue">manufacture</font> <font color="blue">hepatitis</font> products     or,  if we obtain such product <font color="blue">technology</font>, that we will not be able to     <font color="blue">manufacture</font> <font color="blue">hepatitis</font> products or obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for these     products</td>
    </tr>
    <tr>
      <td>Any of the above <font color="blue">factors may <font color="blue">materially</font></font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business,     prospects, operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success</font> <font color="blue">depends on</font> the <font color="blue">development</font> of <font color="blue">new markets</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in large part, on the <font color="blue">introduction</font> and <font color="blue">acceptance by</font>     hospitals, clinics and <font color="blue">laboratories</font> of our new <font color="blue">diagnostic</font> products and our     ability  to  <font color="blue">broaden sales</font> of our <font color="blue">existing products</font> to current and new     customers</td>
    </tr>
    <tr>
      <td>In order to penetrate the market more <font color="blue">effectively</font>, we will need     to expand our sales and marketing <font color="blue">activities</font> by, among other things:           •   increasing our <font color="blue">sales force</font>,           •   expanding our <font color="blue">promotional <font color="blue">activities</font></font>,                                           7     ______________________________________________________________________         •   developing <font color="blue"><font color="blue">additional</font> third party strategic <font color="blue">distributors</font>hips</font>, and           •   <font color="blue">participating</font> in <font color="blue">trade shows</font></td>
    </tr>
    <tr>
      <td>There is no assurance that these or other <font color="blue">activities</font> or <font color="blue">programs will</font> be     successful</td>
    </tr>
    <tr>
      <td>The failure of such <font color="blue">activities</font> or <font color="blue">programs could</font> have a material     adverse effect on our business, prospects, operating results or financial     condition</td>
    </tr>
    <tr>
      <td>Our own <font color="blue">manufacture</font> of scientific <font color="blue">instruments</font>, reagents and <font color="blue">test kits may</font>     not <font color="blue">provide us with</font> anticipated <font color="blue">cost savings</font> or <font color="blue">competitive</font> advantages</td>
    </tr>
    <tr>
      <td>We have sought to differentiate ourselves from our <font color="blue"><font color="blue">competitors</font> through</font> our     <font color="blue">proprietary</font>  instrument  systems</td>
    </tr>
    <tr>
      <td>While some of our <font color="blue"><font color="blue">competitors</font> offer</font>     <font color="blue">proprietary</font> <font color="blue">instruments</font>, other <font color="blue">competitors</font> use third-parties to <font color="blue">manufacture</font>     these <font color="blue">instruments</font> for them</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> our Mago^® Plus and Aptus^®     <font color="blue">instruments</font>, as well as our <font color="blue">new <font color="blue">proprietary</font></font> PARSEC^™ System, at Delta, our     wholly-owned subsidiary in Italy</td>
    </tr>
    <tr>
      <td>Additionally, our wholly-owned subsidiary,     ImmunoVision, produces <font color="blue">certain autoimmune reagents</font> and our wholly-owned     subsidiary,  Diamedix,  produces <font color="blue"><font color="blue">diagnostic</font> test kits</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that we will realize <font color="blue">cost savings</font> or <font color="blue">competitive</font> advantages from     our own production of scientific <font color="blue">instruments</font>, reagents or test kits</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font> may not result in <font color="blue">commercially</font>     <font color="blue">successful products</font></td>
    </tr>
    <tr>
      <td>We devote substantial resources to research and <font color="blue">development</font> to update and     improve  our <font color="blue">existing products</font>, as well as to develop <font color="blue">new products</font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>During 2005, we spent approximately dlra1dtta8 million on our     research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We may in the <font color="blue">future increase</font> the amounts     we <font color="blue">spend on research</font> and <font color="blue">development</font> depending upon, among other things:           •   the outcome of <font color="blue">clinical testing</font> of products under <font color="blue">development</font>,           •   delays or changes in <font color="blue">government</font> required testing or approval     procedures,           •   <font color="blue">technological</font> and <font color="blue">competitive</font> <font color="blue">development</font>s,           •   <font color="blue">strategic marketing <font color="blue">decisions</font></font>, and           •   liquidity</td>
    </tr>
    <tr>
      <td>As a result, our research and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font> may <font color="blue">adversely</font> impact     our earnings in the short term</td>
    </tr>
    <tr>
      <td>Additionally, there is no assurance that:           •   our research and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font> will result in the     <font color="blue">development</font> of <font color="blue">new products</font> or <font color="blue">product enhancements</font>,           •   we will <font color="blue">successfully</font> complete products currently under <font color="blue">development</font>,           •   we will obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, or           •   any <font color="blue">approved product will</font> be produced in commercial quantities, at     <font color="blue">reasonable costs</font>, and be <font color="blue">successfully</font> marketed</td>
    </tr>
    <tr>
      <td>The markets for our products are highly <font color="blue">competitive</font> and subject to rapid     <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>The markets for our products are highly <font color="blue">competitive</font> and are <font color="blue">characterized by</font>     continual and rapid <font color="blue">technological</font> <font color="blue">development</font>s that have resulted, and will     <font color="blue">likely continue</font> to result, in substantial <font color="blue">improvements</font> in <font color="blue">product function</font>     and  performance</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, on our ability to     anticipate changes in <font color="blue">technology</font> and <font color="blue">industry <font color="blue">requirements</font></font> and to respond to     <font color="blue">technological</font> <font color="blue">development</font>s on a <font color="blue">timely basis</font> either <font color="blue">internally</font> or through     <font color="blue">strategic alliances</font></td>
    </tr>
    <tr>
      <td>Several companies have developed, or are developing,     scientific                                           8     ______________________________________________________________________       <font color="blue">instruments</font> and assays that compete or <font color="blue">will compete directly with products</font>     <font color="blue">marketed by us</font></td>
    </tr>
    <tr>
      <td>Many existing and <font color="blue">potential <font color="blue">competitors</font></font> have <font color="blue">substantially</font>     greater financial, marketing, research, and <font color="blue">technological</font> resources, as well     <font color="blue">as established reputations</font> for success in developing, manufacturing, selling     and  servicing  <font color="blue">products than us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>that are more vertically     <font color="blue">integrated than us may</font> have more <font color="blue">flexibility</font> to compete <font color="blue">effectively</font> on     price</td>
    </tr>
    <tr>
      <td>We  expect  that existing and <font color="blue">new <font color="blue"><font color="blue">competitors</font> will</font> continue</font> to     <font color="blue">introduce products</font> or services that are, directly or <font color="blue">indirectly</font>, <font color="blue">competitive</font>     with those <font color="blue">sold by us</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue"><font color="blue">competitors</font> may</font> succeed in developing products     that are more functional or <font color="blue">less costly than</font> those <font color="blue">sold by us</font> and may be     more successful in <font color="blue">marketing such products</font></td>
    </tr>
    <tr>
      <td>These and other changes and     <font color="blue">innovations</font> in the rapidly changing medical <font color="blue">technology</font> market may negatively     affect the sales of the products we market</td>
    </tr>
    <tr>
      <td>There can be no assurance that     we will be able to compete <font color="blue">successfully</font> in this market or that <font color="blue">technology</font>     <font color="blue">development</font>s by our <font color="blue"><font color="blue">competitors</font> will</font> not render our products or <font color="blue">technologies</font>     obsolete</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">effectively</font> compete or adapt to changing <font color="blue">technology</font>,     it  could  have  a material adverse effect on our business, prospects,     operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> <font color="blue">key personnel</font>, the loss of <font color="blue">whom could disrupt</font> our     business</td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">dependent on</font> the <font color="blue">active participation</font> of our principal     <font color="blue">executive officers</font></td>
    </tr>
    <tr>
      <td>The loss of the services of any of these <font color="blue">individuals</font>     could <font color="blue"><font color="blue">adversely</font> affect</font> our business and <font color="blue">future prospects</font></td>
    </tr>
    <tr>
      <td>In addition, our     success  is  <font color="blue">dependent on</font> our ability to retain and <font color="blue">attract <font color="blue">additional</font></font>     qualified <font color="blue">management</font>, scientists, engineers, developers, and <font color="blue">regulatory</font> and     other personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for such talent is intense and there can be no     assurance that we will be able to attract and retain such personnel</td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">dependent on</font> third-party <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>Although our direct <font color="blue">sales force</font> consummates the majority of our sales, we     also engage third-party <font color="blue">distributors</font> to sell our products</td>
    </tr>
    <tr>
      <td>In Italy, our     products are <font color="blue">sold directly through</font> Delta’s independent <font color="blue">sales force</font> and sales     <font color="blue">representatives</font>,  most of whom work <font color="blue">exclusively</font> for Delta</td>
    </tr>
    <tr>
      <td>There is no     assurance that third-party <font color="blue">distributors</font> or <font color="blue">independent <font color="blue">sales personnel</font> will</font>     achieve  acceptable  levels  of  sales or that, if any of our existing     <font color="blue">arrangements</font>  expire  or  terminate,  we  will  be able to replace any     <font color="blue">distributors</font> or <font color="blue"><font color="blue">sales personnel</font> on terms <font color="blue">advantageous</font></font> to us, or at all</td>
    </tr>
    <tr>
      <td>Further,  there  is  no  assurance  that we will be able to expand our     <font color="blue">distribution</font> network by adding <font color="blue">additional</font> <font color="blue">distributors</font> or <font color="blue">sales personnel</font></td>
    </tr>
    <tr>
      <td>If third-party <font color="blue">distributors</font> or independent <font color="blue">sales personnel</font> cease to promote     our products, or if we are unable to make acceptable <font color="blue">arrangements</font> with     <font color="blue">distributors</font> or <font color="blue">sales personnel</font> in other markets, our business, prospects,     operating results or <font color="blue">financial condition</font> could be <font color="blue">materially</font> <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We  depend  on  our  <font color="blue">proprietary</font> rights and cannot be certain of their     <font color="blue">confidentiality</font> and protection</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in large part, on our ability to protect our current     and future <font color="blue">technologies</font> and products and to defend our <font color="blue">intellectual property</font>     rights</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">filed several <font color="blue">patent <font color="blue">application</font>s</font></font> related to the new     innovative features in the PARSEC^™ System</td>
    </tr>
    <tr>
      <td>However, we cannot be sure that     we will receive patents for any of these <font color="blue">patent <font color="blue">application</font>s</font> or that any     patents  that  we  receive will provide <font color="blue">competitive</font> advantages for the     PARSEC^™ System</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be sure that <font color="blue"><font color="blue">competitors</font> will</font> not challenge,     invalidate or void the <font color="blue">application</font> of these patents</td>
    </tr>
    <tr>
      <td>In addition, patent     <font color="blue">rights may</font> not prevent our <font color="blue"><font color="blue">competitors</font> from</font> developing, using or selling     products that are similar or <font color="blue">functionally equivalent</font> to our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">technology</font> <font color="blue">associated with</font> the design and <font color="blue">manufacture</font> of the Mago^® Plus     and Aptus^® <font color="blue">instruments</font> is not <font color="blue">protected by patent registrations</font> or license     <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue"><font color="blue">competitors</font> will</font> not gain     access to our <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> and confidential <font color="blue">technologies</font>,     or that they will not <font color="blue">independently</font> develop similar or <font color="blue">competing trade</font>     secrets and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If others develop competing <font color="blue">instruments</font> or other     products, then this <font color="blue">could erode</font> our <font color="blue">competitive</font> advantage and <font color="blue">materially</font>     harm our business</td>
    </tr>
    <tr>
      <td>We  also  rely  on  <font color="blue">trade secrets</font>, unpatented <font color="blue">proprietary</font> know-how and     continuing <font color="blue">technological</font> innovation</td>
    </tr>
    <tr>
      <td>We use <font color="blue">confidentiality</font> <font color="blue">agreement</font>s with     licensees, suppliers, employees and <font color="blue">consultants</font> to protect our trade                                           9     ______________________________________________________________________       secrets,  unpatented <font color="blue">proprietary</font> know-how and continuing <font color="blue">technological</font>     innovation</td>
    </tr>
    <tr>
      <td>There can be no assurance that these <font color="blue">parties will</font> not breach     their  <font color="blue">agreement</font>s with us</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be certain that we will have     adequate  remedies  for  any breach</td>
    </tr>
    <tr>
      <td>Disputes may arise <font color="blue">concerning</font> the     ownership of <font color="blue">intellectual property</font> or the <font color="blue">applicability</font> of <font color="blue">confidentiality</font>     <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be sure that our <font color="blue">trade secrets</font> and     <font color="blue">proprietary</font>  <font color="blue">technology</font>  will  not  <font color="blue">otherwise become known</font> or that our     <font color="blue">competitors</font>  will not <font color="blue">independently</font> develop similar or <font color="blue">competing trade</font>     secrets and <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be sure, if we do not     receive patents for products arising <font color="blue">from research</font>, that we will be able to     maintain the <font color="blue">confidentiality</font> of information relating to our products</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that we infringe their <font color="blue">proprietary</font> rights, which may     <font color="blue">prevent us from manufacturing</font> and selling some of our products or result in     claims for substantial damages</td>
    </tr>
    <tr>
      <td>Technology-based companies are often very litigious and are often subject to     <font color="blue">unforeseen <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>Therefore, although our business <font color="blue">philosophy</font> is to     respect <font color="blue">intellectual property</font> rights, we face the risk of adverse claims and     <font color="blue">litigation</font> alleging <font color="blue">infringement</font> of <font color="blue">intellectual property</font> rights belonging     to others</td>
    </tr>
    <tr>
      <td>These claims could result in costly <font color="blue">litigation</font> and <font color="blue">could divert</font>     <font color="blue">management</font>’s and technical personnel’s attention from other matters</td>
    </tr>
    <tr>
      <td>The     outcome of any claim is <font color="blue">difficult</font> to predict because of the <font color="blue">uncertainties</font>     inherent  in  <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, regardless of the merits of any     <font color="blue">infringement</font>  claims, these claims could cause us to lose our right to     develop our <font color="blue">discoveries</font> or <font color="blue">commercialize</font> our products in <font color="blue">certain markets</font> or     could require us to <font color="blue">pay monetary damages</font> or royalties to license <font color="blue">proprietary</font>     <font color="blue">rights from third parties</font></td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be certain that we would     be able to obtain these <font color="blue">licenses on terms</font> we believe to be acceptable</td>
    </tr>
    <tr>
      <td>As a     result, an adverse <font color="blue">de<font color="blue">termination</font></font> in a judicial or <font color="blue"><font color="blue">administrative</font> proceeding</font>     or failure to obtain <font color="blue">necessary licenses could</font> have a material and adverse     effect on our business, prospects, operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trend towards <font color="blue">consolidation</font></font> in the <font color="blue"><font color="blue">diagnostic</font>s</font> industry may <font color="blue">adversely</font>     <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">diagnostic</font>s</font> industry has experienced considerable <font color="blue"><font color="blue">consolidation</font> through</font>     mergers and <font color="blue"><font color="blue">acquisition</font>s</font> in the <font color="blue">past several years</font></td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">consolidation</font> trend</font>     may result in the <font color="blue">remaining companies</font> having <font color="blue">greater financial resources</font> and     <font color="blue">technological</font>  <font color="blue">capabilities</font>,  thereby  <font color="blue">intensifying competition</font> in the     industry, which could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Consolidation  </font>of  our  customers or the formation of group purchasing     <font color="blue">organizations</font>  could  result  in <font color="blue">increased pricing pressure</font> that could     <font color="blue"><font color="blue">adversely</font> affect</font> our operating results</td>
    </tr>
    <tr>
      <td>The <font color="blue">health care industry</font> has <font color="blue">undergone <font color="blue">significant</font> <font color="blue">consolidation</font></font> resulting     in <font color="blue">increased purchasing leverage</font> for customers and <font color="blue"><font color="blue">consequently</font> increased</font>     <font color="blue">pricing pressures on</font> our business</td>
    </tr>
    <tr>
      <td>Additionally, some of our customers have     <font color="blue">become affiliated with</font> group purchasing <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Group purchasing     <font color="blue">organizations</font> typically offer members price <font color="blue">discounts</font> on laboratory supplies     and equipment if they purchase a bundled group of one supplier’s products,     which results in a reduction in the number of <font color="blue">manufacture</font>rs selected to     <font color="blue">supply products</font> to the group <font color="blue">purchasing organization</font> and increases the group     purchasing  organization’s  ability  to  influence its members’ buying     <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Further  </font><font color="blue">consolidation</font>  <font color="blue">among customers</font> or their continued     <font color="blue">affiliation with</font> group purchasing <font color="blue">organizations</font> may result in <font color="blue">significant</font>     pricing  pressures and <font color="blue"><font color="blue">corresponding</font>ly reduce</font> the gross margins of our     business  or  may cause our customers to reduce their purchases of our     products thereby <font color="blue"><font color="blue">adversely</font> affect</font>ing our business, prospects, operating     results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Additionally, in Italy, and most other countries in Western Europe, our     products are <font color="blue">sold predominantly</font> to public hospital <font color="blue">laboratories</font>, which are     managed by <font color="blue">government</font> structures either directly or <font color="blue">indirectly</font></td>
    </tr>
    <tr>
      <td>In most     cases, our products are <font color="blue">sold through tenders</font> for <font color="blue">multiple year periods</font></td>
    </tr>
    <tr>
      <td>Due     to the <font color="blue">efforts exercised by</font> many <font color="blue">government</font>s to <font color="blue">contain <font color="blue">healthcare costs</font></font>,     there  has been a <font color="blue">constant effort</font> to <font color="blue">consolidate <font color="blue">laboratory units</font></font> and,     <font color="blue">consequently</font>, the <font color="blue">bid process continues</font> to <font color="blue">become even</font> more <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">containment</font> of <font color="blue">healthcare costs</font>,                                           10     ______________________________________________________________________       <font color="blue">consolidation</font> of <font color="blue">laboratory units</font> or increase in the <font color="blue">competitive</font>ness of the     bid  process could <font color="blue"><font color="blue">adversely</font> affect</font> our business, prospects, operating     results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>policies of <font color="blue">third parties could affect</font> the pricing and demand     for our products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">profitability</font>  may be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font>ed by changes in     <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font>al and <font color="blue">private third <font color="blue">party payors</font></font></td>
    </tr>
    <tr>
      <td>The     products we market are <font color="blue">purchased <font color="blue">principally</font> by <font color="blue">healthcare providers</font></font> that     typically bill third <font color="blue">party payors</font> such as <font color="blue">government</font>al programs (eg,     Medicare and Medicaid), <font color="blue">private insurance</font> plans and <font color="blue">managed care</font> plans, for     <font color="blue">healthcare services provided</font> to their patients</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue">reimbursement</font>     policies are subject to rapid and <font color="blue">significant</font> changes in the United States,     at both the federal and state levels, and in other countries</td>
    </tr>
    <tr>
      <td>Private third     <font color="blue">party payors</font> are <font color="blue">increasingly negotiating</font> the <font color="blue">prices charged</font> for medical     products and services</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">healthcare providers</font>     will not respond to such pressures by substituting <font color="blue">competitors</font>’ products for     our products</td>
    </tr>
    <tr>
      <td>A third party payor may deny <font color="blue">reimbursement</font> if it determines     that a device was not used in <font color="blue">accordance</font> with cost-effective treatment     methods, was <font color="blue">experimental</font>, or for other reasons</td>
    </tr>
    <tr>
      <td>There can be no assurance     that our <font color="blue">products will qualify</font> for <font color="blue">reimbursement</font> by <font color="blue">government</font>al programs in     <font color="blue"><font color="blue">accordance</font> with guidelines established by</font> the <font color="blue">Centers for Medicare </font>and     Medicaid Services, by state <font color="blue">government</font> payors, or <font color="blue">by commercial insurance</font>     carriers, or that <font color="blue">reimbursement</font> will be available in other countries</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">containment</font> measures and <font color="blue">health care reform proposals could affect</font> our     ability to sell our products</td>
    </tr>
    <tr>
      <td>Various <font color="blue">legislative proposals</font>, including proposals relating to the cost     <font color="blue">containment</font>  of  <font color="blue">healthcare products</font> and the <font color="blue"><font color="blue">reimbursement</font> policies</font> of     <font color="blue">government</font>al and <font color="blue">private third <font color="blue">party payors</font></font>, could <font color="blue">materially</font> impact the     pricing and sale of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font><font color="blue">policies may</font> not include our     products</td>
    </tr>
    <tr>
      <td>Even  if  <font color="blue">reimbursement</font>  policies  of  third  <font color="blue">parties grant</font>     <font color="blue">reimbursement</font>  status  for  a  product,  we  cannot be sure that these     <font color="blue"><font color="blue">reimbursement</font> policies</font> will remain in effect</td>
    </tr>
    <tr>
      <td>Limits on <font color="blue">reimbursement</font> could     reduce the demand for our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">unavailability</font> or <font color="blue">inadequacy</font> of     third  party  <font color="blue">reimbursement</font>  for our products could reduce or possibly     eliminate  demand  for  our products</td>
    </tr>
    <tr>
      <td>We are unable to <font color="blue">predict whether</font>     <font color="blue">government</font>al authorities will enact <font color="blue">additional</font> legislation or regulation     <font color="blue">which will affect third party coverage</font> and <font color="blue">reimbursement</font> that <font color="blue">reduces demand</font>     for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with <font color="blue">government</font>al regulation is critical to our business</td>
    </tr>
    <tr>
      <td>The  products  we sell are subject to extensive <font color="blue">regulation by numerous</font>     <font color="blue">government</font>al and <font color="blue">regulatory</font> authorities in the United States, <font color="blue">principally</font>     the FDA, and other countries</td>
    </tr>
    <tr>
      <td>Such regulation includes the regulation of the     testing, approval, manufacturing, labeling, marketing and sale of <font color="blue">diagnostic</font>     devices</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> these <font color="blue">government</font>al <font color="blue">regulations</font> can result in     fines, <font color="blue">unanticipated</font> compliance <font color="blue"><font color="blue">expenditure</font>s</font>, <font color="blue">interruptions</font> of production     and criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> is rigorous, time consuming and     costly</td>
    </tr>
    <tr>
      <td>There is no assurance that <font color="blue">necessary approvals will</font> be <font color="blue">attained on</font> a     <font color="blue">timely basis</font>, if at all, or at the anticipated cost</td>
    </tr>
    <tr>
      <td>In addition, product     approvals can be withdrawn if we fail to <font color="blue">comply with</font> <font color="blue">regulatory</font> standards or     if <font color="blue">unforeseen problems</font> occur <font color="blue">following initial marketing</font></td>
    </tr>
    <tr>
      <td>In  addition, as a general matter, foreign <font color="blue">regulatory</font> <font color="blue">requirements</font> for     <font color="blue">medical devices</font> are <font color="blue">becoming increasingly stringent</font></td>
    </tr>
    <tr>
      <td>“CE Marking” must be     obtained for all <font color="blue">medical devices</font> <font color="blue">commercially</font> distributed in the European     Union, <font color="blue">even though</font> the <font color="blue">products may</font> have received FDA clearance</td>
    </tr>
    <tr>
      <td>In order to     be <font color="blue">commercially</font> distributed throughout the European Union, certain of our     <font color="blue">products must bear</font> the “CE Marking</td>
    </tr>
    <tr>
      <td>” All of the products that we currently     <font color="blue">sell throughout</font> the <font color="blue">European Union </font>are in <font color="blue">conformity with</font> the applicable     “CE” <font color="blue">regulations</font> under the <font color="blue">In Vitro Diagnostics Directive</font></td>
    </tr>
    <tr>
      <td>However, if in     the future we lose the <font color="blue">authorization</font> to use                                           11     ______________________________________________________________________       the “CE Marking,” we may not be able to sell our products in the European     Union,  which  could  have  a material adverse effect on our business,     prospects, operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The evolving and complex     nature of <font color="blue">regulatory</font> <font color="blue">requirements</font>, the <font color="blue">broad authority</font> and <font color="blue">discretion</font> of     <font color="blue">regulatory</font> authorities and the <font color="blue">extremely high level</font> of <font color="blue">regulatory</font> oversight     result in a <font color="blue">continuing possibility</font> that we may be <font color="blue"><font color="blue">adversely</font> affect</font>ed by     <font color="blue">regulatory</font>  actions  despite  our  efforts to maintain <font color="blue">compliance with</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Delays in obtaining, or the <font color="blue">inability</font> to obtain,     <font color="blue">necessary domestic</font> or foreign <font color="blue"><font color="blue">regulatory</font> approval</font>s, failures to <font color="blue">comply with</font>     applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> or extensive changes in <font color="blue">regulation could</font>     have a material adverse effect on our business, prospects, operating results     or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We  are subject to a number of <font color="blue">regulatory</font> and contractual <font color="blue">restrictions</font>     governing our <font color="blue">relations with</font> our employees in Italy</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">employment</font> relations</font> in Italy are governed by numerous <font color="blue">regulatory</font> and     <font color="blue">contractual <font color="blue">requirements</font></font>, including, among other things, national collective     labor  <font color="blue">agreement</font>s  and  individual  employer  labor  <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">arrangements</font> address a number of <font color="blue">specific issues <font color="blue">affecting</font></font> our working     <font color="blue">conditions</font>, including, without <font color="blue">limitation</font>, hiring, work time, wages and     benefits, and <font color="blue">termination</font> of <font color="blue">employment</font></td>
    </tr>
    <tr>
      <td>We must make <font color="blue">significant</font> payments     in order to <font color="blue">comply with</font> these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">complying with</font> these     <font color="blue">requirements</font>  may <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font> our business, prospects,     operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">products could fail</font> to perform <font color="blue">according</font> to <font color="blue">specification</font>, or prove to     be unreliable, which could damage our <font color="blue">customer <font color="blue">relationships</font></font> and industry     reputation and result in lawsuits and loss of sales</td>
    </tr>
    <tr>
      <td>Our customers require demanding <font color="blue">specification</font>s for <font color="blue">product performance</font> and     <font color="blue">re<font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>Because the products we market are complex and often use     state-of-the-art <font color="blue">components</font>, processes and <font color="blue">techniques</font>, undetected errors and     design flaws may occur</td>
    </tr>
    <tr>
      <td>Product defects result in <font color="blue">higher product service</font>,     warranty and <font color="blue">replacement costs</font> and may cause <font color="blue">serious damage</font> to our customer     <font color="blue">relationships</font> and <font color="blue">industry reputation</font>, all of <font color="blue">which will negatively impact</font>     our sales and business</td>
    </tr>
    <tr>
      <td>We may be subject to lawsuits if any of the products     we <font color="blue">market fails</font> to operate properly or causes any ailment to be undiagnosed     or <font color="blue">misdiagnosed</font></td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product <font color="blue">liability</font></font> claims and there can be no assurance     of <font color="blue">adequate insurance</font></td>
    </tr>
    <tr>
      <td>Like all <font color="blue"><font color="blue">diagnostic</font>s</font> companies, the testing, manufacturing and marketing of     our <font color="blue">products may</font> expose us to <font color="blue">product <font color="blue">liability</font></font> and other claims resulting     from their use</td>
    </tr>
    <tr>
      <td>If any such claims against us are successful, we may be     required to make <font color="blue">significant</font> <font color="blue">compensation</font> payments and suffer the associated     adverse publicity</td>
    </tr>
    <tr>
      <td>Even <font color="blue">unsuccessful</font> claims could result in the <font color="blue">expenditure</font>     of funds in <font color="blue">litigation</font> and the diversion of <font color="blue">management</font> time and resources</td>
    </tr>
    <tr>
      <td>We  believe  that  we maintain an <font color="blue">adequate amount</font> of <font color="blue">product <font color="blue">liability</font></font>     insurance, but there can be no assurance that our <font color="blue">insurance will cover</font> all     existing and future claims or that we will be able to maintain existing     coverage or obtain <font color="blue"><font color="blue">additional</font> coverage at reasonable rates</font></td>
    </tr>
    <tr>
      <td>If a claim is     not covered or if our coverage is insufficient, we may incur <font color="blue">significant</font>     <font color="blue">liability</font>  payments  that  would have a material adverse effect on our     business, operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Damages to or <font color="blue">disruptions at</font> our facilities could <font color="blue">adversely</font> impact our     ability to <font color="blue">effectively</font> operate our business</td>
    </tr>
    <tr>
      <td>A portion of our facilities, as well as our <font color="blue">corporate headquarters</font> and other     critical business functions, are located in Miami, Florida—an area subject     to <font color="blue">hurricane casualty risk</font></td>
    </tr>
    <tr>
      <td>Although we have certain limited protection     afforded  by  insurance, our business and <font color="blue">earnings could</font> be <font color="blue">materially</font>     <font color="blue"><font color="blue">adversely</font> affect</font>ed in the event of a <font color="blue">major windstorm</font></td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________       We have limited operating revenue and a history of <font color="blue">primarily operational</font>     losses</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, we <font color="blue">recorded <font color="blue">net revenues</font></font> of dlra19dtta8     million and net loss of dlra0dtta5 million</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2004,     we <font color="blue">recorded <font color="blue">net revenues</font></font> of dlra18dtta9 million and net income of dlra0dtta2 million</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2003, we <font color="blue">recorded <font color="blue">net revenues</font></font> of dlra17dtta7     million and net loss of dlra0dtta7 million</td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal source</font> of short-term     liquidity is, and during the <font color="blue">past three years</font> has been, <font color="blue">existing cash</font> and     <font color="blue">cash <font color="blue">equivalents</font></font> and <font color="blue">marketable securities</font> received as a result of cash     received from the <font color="blue">completion</font> of the merger between b2bstores</td>
    </tr>
    <tr>
      <td>com and the     pre-merger IVAX Diagnostics, which we believe will be sufficient to meet our     operating needs and anticipated capital <font color="blue"><font color="blue">expenditure</font>s</font> over the <font color="blue">next twelve</font>     months</td>
    </tr>
    <tr>
      <td>For the long term, we intend to utilize <font color="blue">principally</font> <font color="blue">existing cash</font>     and  <font color="blue">cash <font color="blue">equivalents</font></font> and <font color="blue">marketable securities</font>, as well as <font color="blue">internally</font>     generated funds, which we anticipate will be derived primarily from our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There is, however, no assurance that <font color="blue">existing cash</font> and cash     <font color="blue">equivalents</font>  and  marketable  securities  <font color="blue">will satisfy</font> all of our cash     <font color="blue">requirements</font> and fund any losses from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, there can be     no  assurance that we will be able to operate on a <font color="blue">profitable basis</font> or     <font color="blue">internally</font> generate <font color="blue">funds from</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">existing cash</font> and cash     <font color="blue">equivalents</font> and <font color="blue">marketable securities</font> are insufficient to finance <font color="blue">operations</font>     of if we are unable to operate on a <font color="blue">profitable basis</font> or <font color="blue">internally</font> generate     <font color="blue">funds from</font> our <font color="blue">operations</font>, then we may be required to <font color="blue">issue securities</font> or     incur  <font color="blue">indebtedness</font> to finance our <font color="blue">operations</font> or curtail or reduce our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to collect our <font color="blue"><font color="blue">accounts</font> receivable</font>, our operating results could     be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>We  maintain  an  allowance for <font color="blue">doubtful <font color="blue">accounts</font></font> for estimated losses     resulting from the <font color="blue">inability</font> of our customers to make required payments</td>
    </tr>
    <tr>
      <td>As     of <font color="blue">December </font>31, 2005 and 2004, our <font color="blue"><font color="blue">accounts</font> receivable</font> were dlra7dtta7 million and     dlra10dtta8 million, <font color="blue">respectively</font>, and our allowance for <font color="blue">doubtful <font color="blue">accounts</font></font> was     dlra1dtta0  million and dlra3dtta1 million</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005 and 2004, dlra5dtta3     million and dlra8dtta6 million, <font color="blue">respectively</font>, of our <font color="blue"><font color="blue">accounts</font> receivable</font> were due     in Italy, and dlra0dtta7 million and dlra2dtta7 million, <font color="blue">respectively</font>, of our allowance     for <font color="blue">doubtful <font color="blue">accounts</font></font> related <font color="blue">to Italian </font><font color="blue"><font color="blue">accounts</font> receivable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately     </font>90prca of Delta’s customers in Italy are <font color="blue">government</font> owned hospitals and the     remaining 10prca are private <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005 and 2004,     57dtta0prca and 64dtta8prca, <font color="blue">respectively</font>, of our net <font color="blue"><font color="blue">accounts</font> receivable</font> were due from     hospitals  and  <font color="blue">laboratories</font>  controlled  by  the  Italian <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>Accordingly, we are subject to credit risk if the Italian <font color="blue">government</font> does     not, or is not able to, <font color="blue">pay amounts owed</font> to us</td>
    </tr>
    <tr>
      <td>In  many  instances, our <font color="blue">receivables</font> in Italy, <font color="blue">while currently due</font> and     payable, take in excess of a year to collect and, although untimely, most     customers have <font color="blue">historically paid</font> the amounts they owe</td>
    </tr>
    <tr>
      <td>Nevertheless, there     is no assurance that we <font color="blue">will collect</font> the outstanding <font color="blue"><font color="blue">accounts</font> receivable</font> or     that the allowance for <font color="blue">doubtful <font color="blue">accounts</font></font> will be adequate</td>
    </tr>
    <tr>
      <td>The failure to     collect outstanding <font color="blue">receivables</font>, whether relating to Italy, the United     States or elsewhere, could have a material adverse effect on our business,     prospects,  operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If the financial     condition of our customers was to <font color="blue">deteriorate</font>, resulting in an <font color="blue">impairment</font> of     their ability to make payments, then we may be required to make <font color="blue">additional</font>     <font color="blue">allowances</font>, which would <font color="blue"><font color="blue">adversely</font> affect</font> our operating results in the period     in which the <font color="blue">de<font color="blue">termination</font></font> or allowance is or was made</td>
    </tr>
    <tr>
      <td>Political and economic <font color="blue">instability</font> and foreign currency <font color="blue">fluctuations</font> may     <font color="blue"><font color="blue">adversely</font> affect</font> the revenues generated by our foreign <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For     the years ended <font color="blue">December </font>31, 2005, 2004 and 2003, Delta represented 34dtta7prca,     36dtta0prca  and  33dtta8prca,  <font color="blue">respectively</font>,  of  our <font color="blue">net revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font>an     <font color="blue">international</font> business <font color="blue">inherently</font> involves a number of <font color="blue">difficult</font>ies, risks     and <font color="blue">uncertainties</font>, such as:           •   export and trade <font color="blue">restrictions</font>,           •   <font color="blue">inconsistent</font> and changing <font color="blue">regulatory</font> <font color="blue">requirements</font>,           •   tariffs and other <font color="blue">trade barriers</font>,           •   <font color="blue">cultural issues</font>,                                           13     ______________________________________________________________________         •   <font color="blue">longer payment cycles</font>,           •   problems in collecting <font color="blue"><font color="blue">accounts</font> receivable</font>,           •   political <font color="blue">instability</font>,           •   <font color="blue">local economic downturns</font>,           •   <font color="blue">seasonal reductions</font> in business activity in Europe during the     <font color="blue">traditional summer vacation months</font>, and           •   <font color="blue">potentially adverse tax consequences</font></td>
    </tr>
    <tr>
      <td>For the years ended <font color="blue">December </font>31, 2005, 2004 and 2003, 34dtta7prca, 36dtta0prca and 33dtta8prca     of our net revenue, <font color="blue">respectively</font>, were generated in currencies other than     the <font color="blue">United States </font>dollar</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in the value of <font color="blue">foreign currencies</font>     relative to the <font color="blue">United States </font><font color="blue">dollar affect</font> our operating results</td>
    </tr>
    <tr>
      <td>For     instance,  if the <font color="blue">United States </font><font color="blue">dollar strengthens relative</font> to foreign     currency, then our <font color="blue">earnings generated</font> in <font color="blue">foreign currency will</font>, in effect,     decrease when <font color="blue">converted into</font> <font color="blue">United States </font>dollars, which could have a     material  and  adverse  effect on our operating results</td>
    </tr>
    <tr>
      <td>We do not use     <font color="blue">financial derivatives</font> to hedge exchange rate <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">use <font color="blue">inventories</font></font> of parts and <font color="blue">products purchased</font> or     made  before  receiving  final  <font color="blue"><font color="blue">regulatory</font> clearance</font> or beginning full     <font color="blue">commercial marketing</font></td>
    </tr>
    <tr>
      <td>From time to time, we purchase or make <font color="blue">significant</font> quantities of parts and     <font color="blue">products prior</font> to the <font color="blue">date on which</font> we receive final <font color="blue"><font color="blue">regulatory</font> clearance</font> or     begin  our  full  commercial  marketing</td>
    </tr>
    <tr>
      <td>The production of pre-launch     <font color="blue">inventories</font> for our <font color="blue">products involves</font> the risks, among others, that the     parts and <font color="blue">products may</font> not be approved for <font color="blue">commercial marketing</font> by the     applicable <font color="blue">regulatory</font> authorities on a <font color="blue">timely basis</font>, if at all, or that we     may not be able to <font color="blue">find alternative uses</font> for <font color="blue">such inventory</font></td>
    </tr>
    <tr>
      <td>If any of these     events  were  to  occur or the launch of the products is <font color="blue">significant</font>ly     postponed, then we may be required to reassess the <font color="blue">net realizable value</font> of     the related inventory and could, in such case, incur a charge to write down     the value of <font color="blue">such inventory</font>, which would <font color="blue"><font color="blue">adversely</font> affect</font> our operating     results in the period in which the <font color="blue">de<font color="blue">termination</font></font> or charge is or was made</td>
    </tr>
    <tr>
      <td>There  are inherent <font color="blue">uncertainties</font> involved in estimates, judgments and     <font color="blue">assumptions</font> used in the <font color="blue">preparation</font> of <font color="blue">financial statements</font> in <font color="blue">accordance</font>     with <font color="blue">United States </font>GAAP Any changes in estimates, judgments and <font color="blue">assumptions</font>     used  could  have a material adverse effect on our business, financial     position and operating results</td>
    </tr>
    <tr>
      <td>The <font color="blue">consolidated <font color="blue">financial statements</font></font> included in the periodic reports we     file with the <font color="blue">Securities and Exchange Commission </font>are prepared in <font color="blue">accordance</font>     with  <font color="blue"><font color="blue">accounting</font> principles generally accepted</font> in the <font color="blue">United States </font>of     America, or GAAP The <font color="blue">preparation</font> of <font color="blue">financial statements</font> in <font color="blue">accordance</font> with     GAAP  involves making estimates, judgments and <font color="blue">assumptions</font> that affect     reported amounts of assets (including <font color="blue">intangible assets</font>), <font color="blue">liabilities</font> and     related reserves, revenues, expenses and income</td>
    </tr>
    <tr>
      <td>This includes estimates,     judgments and <font color="blue">assumptions</font> for assessing the <font color="blue">recoverability</font> of our goodwill     and other <font color="blue">intangible assets</font>, pursuant to <font color="blue">Statement </font>of Financial Accounting     Standards (SFAS) Nodtta 142, Goodwill and Other Intangible Assets, and SFAS     Nodtta 144, Accounting for the Impairment or Disposal of Long-Lived Assets</td>
    </tr>
    <tr>
      <td>If     any estimates, judgments or <font color="blue">assumptions</font> change in the future, we may be     required to record <font color="blue">additional</font> expenses or <font color="blue">impairment</font> charges</td>
    </tr>
    <tr>
      <td>Any resulting     expense  or  <font color="blue">impairment</font> loss would be <font color="blue">recorded as</font> a <font color="blue">charge against</font> our     earnings and could have a material <font color="blue">adverse impact on</font> our <font color="blue">financial condition</font>     and operating results</td>
    </tr>
    <tr>
      <td>Estimates, judgments and <font color="blue">assumptions</font> are <font color="blue">inherently</font>     subject  to change in the future, and any such changes could result in     <font color="blue">corresponding</font> changes to the amounts of assets (including goodwill and other     <font color="blue">intangible assets</font>), <font color="blue">liabilities</font>, revenues, expenses and income</td>
    </tr>
    <tr>
      <td>Any such     changes could have a material adverse effect on our <font color="blue">financial position</font> and     operating results</td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________       On an on-going basis, we evaluate our estimates, including, among others,     those relating to:           •   product returns,           •   <font color="blue">allowances</font> for <font color="blue">doubtful <font color="blue">accounts</font></font>,           •   <font color="blue">inventories</font> and related reserves,           •   <font color="blue">intangible assets</font>,           •   income and other <font color="blue">tax accruals</font>,           •   deferred tax asset valuation <font color="blue">allowances</font>,           •   <font color="blue">discounts</font> and <font color="blue">allowances</font>,           •   <font color="blue">warranty <font color="blue">obligations</font></font>, and           •   <font color="blue">contingencies</font> and <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>We  base  our  estimates on historical experience and on various other     <font color="blue">assumptions</font> that we believe to be <font color="blue">reasonable under</font> the <font color="blue">circumstances</font>, the     results of which form the basis for making <font color="blue">judgments about</font> the carrying     values of assets and <font color="blue">liabilities</font> that are not <font color="blue">readily apparent from</font> other     sources</td>
    </tr>
    <tr>
      <td>Our <font color="blue">assumptions</font> and estimates may, however, prove to have been     incorrect and our actual results <font color="blue">may differ from</font> these estimates under     different <font color="blue">assumptions</font> or <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>While we believe the <font color="blue">assumptions</font> and     estimates  we  make  are reasonable, any changes to our <font color="blue">assumptions</font> or     estimates,  or any actual results <font color="blue">which differ from</font> our <font color="blue">assumptions</font> or     estimates, could have a material adverse effect on our <font color="blue">financial position</font>     and operating results</td>
    </tr>
    <tr>
      <td>Our potential <font color="blue"><font color="blue">acquisition</font>s</font> may reduce our earnings, be <font color="blue">difficult</font> for us to     <font color="blue">combine into</font> our <font color="blue">operations</font> or require us to obtain <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td>In the ordinary course of our business, we evaluate potential business     <font color="blue">acquisition</font> <font color="blue">opportunities</font> that we anticipate will provide new product and     market <font color="blue">opportunities</font>, benefit from and maximize our existing assets and add     critical mass</td>
    </tr>
    <tr>
      <td>We often incur <font color="blue">significant</font> expenses in <font color="blue">connection with</font> our     <font color="blue">evaluation</font> of potential business <font color="blue">acquisition</font> <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>However, we may     not be successful in finding or <font color="blue">consummating</font> any <font color="blue"><font color="blue">acquisition</font>s</font>, and any     <font color="blue"><font color="blue">acquisition</font>s</font>  we make <font color="blue">may expose us</font> to <font color="blue">additional</font> risks and may have a     material adverse effect on our operating results</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">acquisition</font>s</font> we make     may fail to accomplish our strategic objectives, may not be <font color="blue">successfully</font>     <font color="blue">combined with</font> our <font color="blue">operations</font> or may not perform as expected</td>
    </tr>
    <tr>
      <td>In addition,     although we generally seek <font color="blue"><font color="blue">acquisition</font>s</font> that we believe will be <font color="blue">accretive</font> to     our per share earnings, <font color="blue">based on</font> current <font color="blue">acquisition</font> prices in the industry,     our <font color="blue"><font color="blue">acquisition</font>s</font> could initially reduce our earnings and add <font color="blue">significant</font>     <font color="blue">intangible assets</font> and related <font color="blue">amortization charges</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">acquisition</font> strategy     may require us to obtain debt or equity financing, resulting in increased     leverage or increased debt <font color="blue">obligations</font>, as compared to equity, and the     dilution of our <font color="blue">stockholders</font>’ ownership of us</td>
    </tr>
    <tr>
      <td>We may not be able to finance     <font color="blue"><font color="blue">acquisition</font>s</font> on terms satisfactory to us</td>
    </tr>
    <tr>
      <td>The impact of <font color="blue">new <font color="blue">accounting</font> principles could</font> have a material adverse effect     on our operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently account</font> for <font color="blue"><font color="blue">stock options</font> granted</font> to <font color="blue">employees under</font> Accounting     Principles Board Opinion Nodtta 25, <font color="blue">Accounting for Stock Issued to Employees</font></td>
    </tr>
    <tr>
      <td>Under this standard, no <font color="blue">compensation</font> cost is recorded for <font color="blue">stock options</font>     granted  to  employees  at  <font color="blue">fair market value on</font> the date of grant</td>
    </tr>
    <tr>
      <td>On     <font color="blue">December </font>16, 2004, the <font color="blue">Financial Accounting Standards Board </font>issued SFAS     Nodtta 123 (revised 2004), Share-Based Payments, which addresses the <font color="blue">accounting</font>     for <font color="blue"><font color="blue">transaction</font>s</font> in which an entity exchanges its equity <font color="blue">instruments</font> for     goods  or services</td>
    </tr>
    <tr>
      <td><font color="blue">This <font color="blue">Statement </font></font>focuses primarily on <font color="blue">accounting</font> for     <font color="blue"><font color="blue">transaction</font>s</font> in which an entity obtains <font color="blue">employee services</font> in share-based     payment <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">This <font color="blue">Statement </font></font>requires all share-based payments to     employees, including grants of employee <font color="blue">stock options</font>, to be recognized in     the <font color="blue">income statement based upon</font> their <font color="blue">fair values</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the     impact, which may be material, of our adoption of this <font color="blue">Statement </font>primarily     because                                           15     ______________________________________________________________________       the <font color="blue">impact will depend on levels</font> of share-based payments in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Compensation </font><font color="blue">expense will</font> be required to be recorded for vesting of pre-2006     <font color="blue">unvested options</font> and <font color="blue">future awards</font> of share-based payments</td>
    </tr>
    <tr>
      <td><font color="blue">This <font color="blue">Statement </font></font>    and  other  new <font color="blue">accounting</font> principles adopted in the <font color="blue">future may</font> have a     material adverse effect on our <font color="blue">financial condition</font> or operating results</td>
    </tr>
    <tr>
      <td>We will be exposed to risks relating to <font color="blue">evaluation</font>s of <font color="blue">internal control over</font>     financial reporting required by Section 404 of the Sarbanes-Oxley Act of     2002</td>
    </tr>
    <tr>
      <td>We anticipate spending a substantial amount of <font color="blue">management</font> time and resources     to <font color="blue">comply with</font> changing laws, rules, <font color="blue">regulations</font> and standards relating to     <font color="blue">corporate governance</font> and <font color="blue">public disclosure</font>, including the Sarbanes-Oxley Act     of 2002, <font color="blue">regulations</font> promulgated by the <font color="blue">Securities and Exchange Commission </font>    and rules promulgated by <font color="blue">the American Stock Exchange</font></td>
    </tr>
    <tr>
      <td>Under the current rules and <font color="blue">regulations</font> of the Securities and Exchange     Commission, we are currently not required to <font color="blue">comply with</font> the <font color="blue">requirements</font> of     Section 404 of the Sarbanes-Oxley Act of 2002 until we file our Annual     Report on Form 10-K for our <font color="blue">fiscal year</font> ending <font color="blue">December </font>31, 2007, so long as     we continue to meet the <font color="blue">definition</font> of a non-accelerated filer</td>
    </tr>
    <tr>
      <td>In our Annual     Report on Form 10-K for the year ending <font color="blue">December </font>31, 2007, <font color="blue">management</font> will     be required to provide an <font color="blue"><font color="blue">assessment</font> as</font> to the <font color="blue">effectiveness</font> of our internal     <font color="blue">control over financial</font> reporting and our <font color="blue">independent registered public</font>     <font color="blue">accounting</font> firm will be required to attest as to <font color="blue">management</font>’s <font color="blue">assessment</font> and     to the <font color="blue">effectiveness</font> of <font color="blue">internal control over</font> financial reporting</td>
    </tr>
    <tr>
      <td>The     <font color="blue">assessment</font> and <font color="blue">attestation processes</font> required by Section 404 are <font color="blue">relatively</font>     new and <font color="blue">neither companies nor auditing firms</font> have <font color="blue">significant</font> experience in     testing or <font color="blue">complying with</font> these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">may encounter</font>     problems  or  delays  in  completing  our <font color="blue">obligations</font> and receiving an     unqualified report on our <font color="blue">internal control over</font> financial reporting by our     <font color="blue">independent registered public</font> <font color="blue">accounting</font> firm</td>
    </tr>
    <tr>
      <td>While we believe that we will be able to <font color="blue">timely meet</font> our <font color="blue">obligations</font> under     Section 404  and  that  <font color="blue">management</font>  will  be able to <font color="blue">certify as</font> to the     <font color="blue">effectiveness</font> of our <font color="blue">internal controls</font>, there is no assurance that we will     do so</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue"><font color="blue">common stock</font> may</font> be <font color="blue">adverse affected</font> if:           •   we are unable to timely <font color="blue">comply with</font> Section 404,           •   <font color="blue">management</font> is unable to <font color="blue">certify as</font> to the <font color="blue">effectiveness</font> of our     <font color="blue">internal controls</font>, or           •   our <font color="blue">independent registered public</font> <font color="blue">accounting</font> firm is unable to attest     to that <font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">timely meet</font> the <font color="blue">certification</font> and attestation <font color="blue">requirements</font> of     Section 404,  it  is  possible  that our <font color="blue">independent registered public</font>     <font color="blue">accounting</font>  firm  <font color="blue">will advise us</font> that they have identified <font color="blue">significant</font>     deficiencies and/or material weaknesses, which may also <font color="blue"><font color="blue">adversely</font> affect</font> the     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our cash and <font color="blue">cash <font color="blue">equivalents</font></font> and <font color="blue">marketable securities</font>     are held at a <font color="blue">single <font color="blue">brokerage firm</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our cash and <font color="blue">cash <font color="blue">equivalents</font></font> and short-term marketable     securities are presently held <font color="blue">at one national securities <font color="blue">brokerage firm</font></font></td>
    </tr>
    <tr>
      <td>Accordingly, we are subject to credit risk if this <font color="blue">brokerage firm</font> is unable     to repay the balance in the account or deliver our securities or if the     <font color="blue">brokerage firm</font> should become bankrupt or <font color="blue">otherwise insolvent</font></td>
    </tr>
    <tr>
      <td>Any of the     above <font color="blue">events could</font> have a material and adverse effect on our business and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Teva, <font color="blue">indirectly</font> through its wholly-owned IVAX subsidiary, controls our     company</td>
    </tr>
    <tr>
      <td>Teva,  <font color="blue">indirectly</font>  through  its  wholly-owned  IVAX  subsidiary,  owns     approximately 72dtta4prca of the issued and <font color="blue">outstanding shares</font> of our common     stock</td>
    </tr>
    <tr>
      <td>Under our <font color="blue">certificate</font> of incorporation, on issues for which our     <font color="blue">stockholders</font> are eligible to vote, the <font color="blue">affirmative vote</font> of a majority of the     <font color="blue">shares represented at</font> a meeting in person or by proxy, and entitled to vote,     is  required to approve an action</td>
    </tr>
    <tr>
      <td>Consequently, Teva can <font color="blue">unilaterally</font>     approve  actions that require <font color="blue">stockholder approval</font> and <font color="blue">elect <font color="blue">directors</font></font>     acceptable to it <font color="blue">based on</font> its share ownership</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       We may have conflicts of <font color="blue">interest with</font> Teva</td>
    </tr>
    <tr>
      <td><font color="blue">Conflicts </font>of interest may arise between Teva and us in a number of areas     relating to <font color="blue">past matters with</font> IVAX and ongoing matters with Teva, including,     without  <font color="blue">limitation</font>,  labor,  tax, employee benefits, indemnification,     <font color="blue">intellectual property</font>, employee retention and recruiting, major business     <font color="blue">combinations</font>, Teva’s sale or <font color="blue">distribution</font> of all or any portion of its     ownership  interest  in  us,  the  nature,  quality and pricing of the     <font color="blue">administrative</font>  services Teva provides or IVAX has provided to us, and     business <font color="blue">opportunities</font> that might be attractive to both Teva and us</td>
    </tr>
    <tr>
      <td><font color="blue">Teva     </font>may  decide  to  compete  with us in the future, which would create an     <font color="blue">additional</font> conflict of interest</td>
    </tr>
    <tr>
      <td>Three of the former <font color="blue">executive officers</font> of     IVAX, certain of whom are now employees of Teva, are members of our board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>For as long as Teva <font color="blue">controls us</font>, Teva will be able to require us     to agree to amend any <font color="blue">agreement</font>s we have with IVAX or will have with Teva,     even if those <font color="blue">amendments</font> are less favorable to us than the <font color="blue">current terms</font> of     any such <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that any conflicts that may arise     will be resolved in a matter that is favorable to us</td>
    </tr>
    <tr>
      <td>Additionally, even if     we do <font color="blue">resolve such conflicts</font>, the <font color="blue">resolutions may</font> be less favorable to us     than it would be if we were <font color="blue">dealing with</font> an <font color="blue">unaffiliated third party</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">directors</font> have, and certain of our officers and employees may     have, a substantial amount of their personal financial portfolios in <font color="blue">Teva     </font>ADRs</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font>conflicts of <font color="blue">interests may</font> arise if those <font color="blue">directors</font> or     officers are faced with <font color="blue">decisions</font> that could have <font color="blue">different implications</font> for     Teva and us</td>
    </tr>
    <tr>
      <td>Additionally, our financial results will be included in Teva’s     <font color="blue">consolidated <font color="blue">financial statements</font></font> for so long as Teva continues to own at     least 50prca of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">directors</font> who may hold <font color="blue">positions with</font>     Teva, and who may also be holders of Teva ADRs, <font color="blue">may therefore</font> consider not     only  the  short-term  and long-term impact of financial and operating     <font color="blue">decisions</font>  on  us,  but  also  the impact of these <font color="blue">decisions</font> on Teva’s     <font color="blue">consolidated financial</font> results and <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In some instances, these     <font color="blue">decisions</font> could be <font color="blue">dis<font color="blue">advantageous</font></font> to us and <font color="blue">advantageous</font> to Teva</td>
    </tr>
    <tr>
      <td>In 2001, we <font color="blue">entered into</font> a use of name <font color="blue">license <font color="blue">agreement</font> with</font> IVAX whereby     IVAX  <font color="blue">granted us</font> a non-exclusive, royalty free license to use the name     “IVAX” IVAX <font color="blue">may terminate</font> this <font color="blue">license at</font> any time upon 90 days written     notice</td>
    </tr>
    <tr>
      <td>There can be no assurance that IVAX will not terminate this license     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Upon <font color="blue">termination</font> of the <font color="blue">agreement</font>, we are required to take all     steps <font color="blue">reasonably necessary</font> to change our <font color="blue">name as soon as practicable</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">termination</font> of this <font color="blue">agreement</font> could have a material adverse effect on our     business, prospects, operating results or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our stock has a limited <font color="blue">trading volume</font> and a number of internal and external     factors have caused, and <font color="blue">may continue</font> to cause, the <font color="blue">market price</font> of our     stock to be volatile</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> has <font color="blue">only been listed</font> and traded on the American Stock     Exchange since March 15, 2001</td>
    </tr>
    <tr>
      <td>As a result of Teva, through its wholly-owned     IVAX subsidiary, owning approximately 72dtta4prca of the issued and outstanding     shares  of  our  common  stock, we have a limited non-affiliate market     <font color="blue">capitalization</font></td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">common stock</font> has a limited <font color="blue">trading volume</font>,     which makes it more <font color="blue">difficult</font> for our <font color="blue">stockholders</font> to sell their shares</td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">market price</font>s for securities of companies engaged in the     <font color="blue">healthcare field</font>, including us, have <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td>Many factors, including     many over which we have no control, may have a <font color="blue">significant</font> impact on the     future <font color="blue">market price</font> of our <font color="blue">common stock</font>, including, without <font color="blue">limitation</font>:           •   <font color="blue">announcements</font> by us and our <font color="blue">competitors</font> of <font color="blue">technological</font> <font color="blue">innovations</font>,     <font color="blue">new commercial products</font> or <font color="blue">significant</font> contracts or business <font color="blue"><font color="blue">acquisition</font>s</font>,           •   period-to-period changes in our financial results,                                           17     ______________________________________________________________________         •   <font color="blue">market acceptance</font> of existing or <font color="blue">new products</font>,           •   the financial results of, and <font color="blue">announcements</font> made by and <font color="blue">actions taken</font>     by, Teva, and           •   changes in general <font color="blue">conditions</font> in the economy, financial markets or     <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font> or <font color="blue">additional</font> shares of <font color="blue">common stock</font> could     <font color="blue"><font color="blue">adversely</font> affect</font> the rights of the holders of shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> is authorized to issue up to 5cmam000cmam000 shares of     <font color="blue">preferred stock</font> without any <font color="blue">further action on</font> the part of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Currently, we have no shares of <font color="blue">preferred stock</font> outstanding</td>
    </tr>
    <tr>
      <td>In the event     that we issue <font color="blue">preferred stock</font> in the future that has <font color="blue">preference over</font> the     <font color="blue">common stock</font> with respect to payment of dividends or upon our <font color="blue">liquidation</font>,     <font color="blue">dissolution</font> or <font color="blue">winding up</font>, the rights of holders of shares of our common     stock may be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>In addition, the ability of our board of     <font color="blue">directors</font> to issue shares of <font color="blue">preferred stock</font> without any <font color="blue">further action on</font>     the part of our <font color="blue">stockholders</font> may impede a takeover of us and <font color="blue">may prevent</font> a     <font color="blue">transaction</font> that is favorable to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Cautionary <font color="blue">Statement </font>Concerning Forward-Looking Statements          We have made forward-looking statements, which are subject to risks and     <font color="blue">uncertainties</font>, in this <font color="blue">Annual Report </font>on Form 10-K These statements are     based  on  the  beliefs  and  <font color="blue">assumptions</font> of our <font color="blue">management</font> and on the     information <font color="blue">currently available</font> to it</td>
    </tr>
    <tr>
      <td>Forward-looking statements may be     preceded by, followed by, or otherwise include the words “may,” “will,”     “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,”     “projects,” “could,” “would,” “should,” or similar <font color="blue">expressions</font> or statements     that <font color="blue">certain events</font> or <font color="blue">conditions</font> may occur</td>
    </tr>
    <tr>
      <td>Actual results, performance or     achievements could differ <font color="blue">materially</font> from those contemplated, expressed or     implied  by  these  forward-looking  statements</td>
    </tr>
    <tr>
      <td>These forward-looking     statements  are  <font color="blue">based largely on</font> our <font color="blue">expectations</font> and the beliefs and     <font color="blue">assumptions</font> of our <font color="blue">management</font> and on the information <font color="blue">currently available</font> to     it and are subject to a number of risks and <font color="blue">uncertainties</font>, including, but     not limited to, the risks and <font color="blue">uncertainties</font> <font color="blue">associated with</font>:           •   economic, <font color="blue">competitive</font>, political, <font color="blue">government</font>al and other factors     <font color="blue">affecting</font> us and our <font color="blue">operations</font>, markets and products;           •   the success of <font color="blue">technological</font>, strategic and business <font color="blue">initiatives</font>,     including our <font color="blue">automation strategy</font> and our <font color="blue">development</font> and <font color="blue">commercial release</font>     of our <font color="blue">new <font color="blue">proprietary</font></font> instrument system, named the PARSEC^™ System;           •   our ability to receive <font color="blue"><font color="blue">regulatory</font> approval</font> for the PARSEC^™ System;           •   the impact of the delay in the full <font color="blue">commercial launch</font> of the     PARSEC^™ System in the <font color="blue">United States </font>on our <font color="blue">international</font> <font color="blue">activities</font>     <font color="blue">associated with</font> the PARSEC^™ System;           •   the ability of the PARSEC^™ System to be available when or perform as     expected;           •   the ability of the PARSEC^™ System to be a factor in our growth;           •   the ability of the PARSEC^™ System to expand the menu of test kits we     offer;           •   making the PARSEC^™ System our <font color="blue">primary product</font>;           •   our ability to market the PARSEC^™ System;           •   our customers’ integration of the PARSEC^™ System into their     <font color="blue">operations</font>;           •   <font color="blue">constantly</font> changing, and our <font color="blue">compliance with</font>, <font color="blue">government</font>al regulation,     including “European Conformity” marking on our <font color="blue">products sold throughout</font> the     European Union;           •   our ability to update to ISO 13485:2003;                                           18     ______________________________________________________________________         •   our adoption or <font color="blue">implementation</font> of new <font color="blue">accounting</font> statements and     <font color="blue">pronouncements</font>;           •   our limited operating revenues and history of <font color="blue">primarily operational</font>     losses;           •   our ability to collect our <font color="blue"><font color="blue">accounts</font> receivable</font> and to make or change     judgments and estimates regarding our <font color="blue">allowances</font> for <font color="blue">doubtful <font color="blue">accounts</font></font>;           •   our ability to utilize our <font color="blue">deferred tax assets</font> and to make or change     judgments and estimates regarding our valuation <font color="blue">allowances</font> and reserves     against our <font color="blue">deferred tax assets</font>;           •   our ability to achieve <font color="blue">cost advantages from</font> our own <font color="blue">manufacture</font> of     instrument systems, reagents and test kits;           •   our ability to grow beyond the autoimmune and <font color="blue">infectious disease</font>     markets and to expand into <font color="blue">additional</font> <font color="blue">diagnostic</font> test sectors;           •   our ability to <font color="blue">internally</font> <font color="blue">manufacture</font> our own <font color="blue">hepatitis</font> products and     <font color="blue">raw materials</font> for these products, to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for these     products and to become <font color="blue">competitive</font> in <font color="blue">markets outside</font> of the United States;           •   our <font color="blue">agreement</font>s with IVAX, third party <font color="blue">distributors</font> and <font color="blue">key personnel</font>;           •   <font color="blue">consolidation</font> of our customers <font color="blue">affecting</font> our <font color="blue">operations</font>, markets and     products;           •   <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font>al and <font color="blue">private third parties</font>     <font color="blue">affecting</font> our <font color="blue">operations</font>, markets and products;           •   <font color="blue">price constraints imposed by</font> our customers and <font color="blue">government</font>al and     <font color="blue">private third parties</font>;           •   our ability to consummate potential <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">businesses</font> or     products;           •   our ability to integrate acquired <font color="blue">businesses</font> or products;           •   our ability to sell the <font color="blue">current location</font> of our Miami <font color="blue">facility</font> and to     acquire a <font color="blue">new location</font> to which to relocate it;           •   protecting our <font color="blue">intellectual property</font>;           •   political and economic <font color="blue">instability</font> and <font color="blue">foreign currency fluctuation</font>     <font color="blue">affecting</font> our foreign <font color="blue">operations</font>;           •   the holding of <font color="blue">substantially</font> all of our cash and <font color="blue">cash <font color="blue">equivalents</font></font> and     <font color="blue">marketable securities</font> at a <font color="blue">single <font color="blue">brokerage firm</font></font>, including risks relating     to the <font color="blue">bankruptcy</font> or <font color="blue">insolvency</font> of such <font color="blue">brokerage firm</font>;           •   <font color="blue">litigation</font> regarding products, <font color="blue">distribution</font> rights, intellectual     <font color="blue">property rights</font> and <font color="blue">product <font color="blue">liability</font></font>;           •   <font color="blue">voting control</font> of our <font color="blue">common stock</font> by Teva;           •   conflicts of <font color="blue">interest with</font> Teva, IVAX and with our officers, <font color="blue">directors</font>     and employees; and           •   other factors discussed elsewhere in this <font color="blue">Annual Report </font>on Form 10-K         Many of these factors are beyond our control</td>
    </tr>
  </tbody>
</table>